Journal of Clinical Oncology, Vol 7, 1875-1884, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma

W Aulitzky, G Gastl, WE Aulitzky, M Herold, J Kemmler, B Mull, J Frick and C Huber
Department of Urology, General Hospital, Salzburg, Austria.

We tested the clinical efficacy of a biologically active dose (BAD) of interferon (IFN)-gamma for treatment of progressive renal cell carcinoma (RCC). Twenty-two RCC patients with disease progression subsequent to nephrectomy were entered on a phase II clinical trial. During an initial dose-finding phase, biochemical responses to repeated once-weekly subcutaneous injections of 10, 100, or 500 micrograms of recombinant IFN-gamma were tested in 16 patients. Results indicated that 100 micrograms IFN-gamma applied once weekly was biologically active with induction of serum beta 2-microglobulin and neopterin. Such a dose induced a nearly maximum response of both markers lasting more than 4 days. This dose was also associated with minimal side effects. A dose of 100 micrograms IFN-gamma given once weekly was, therefore, subsequently given weekly for long-term treatment. During a median time of therapy of 10 months (range, 2 to 32 months) two complete (CR; 20+, 20+ months) and four partial tumor responses (PR; 6+, 7+, 8+, 24+ months) were seen (30% CR plus PR; 95% confidence limits, 12% to 54%) among 20 patients evaluable for response. Patients with refractory disease had significantly lower IFN-gamma-induced increments of serum beta 2-microglobulin than those who achieved clinical remission or stable disease.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Nakamura, Y. Komagiri, T. Kojo, and M. Kubokawa Delayed and acute effects of interferon-{gamma} on activity of an inwardly rectifying K+ channel in cultured human proximal tubule cells Am J Physiol Renal Physiol, January 1, 2009; 296(1): F46 - F53. [Abstract] [Full Text] [PDF]

				E. M. Messing, J. Manola, G. Wilding, K. Propert, J. Fleischmann, E. D. Crawford, J. E. Pontes, R. Hahn, and D. Trump Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial J. Clin. Oncol., April 1, 2003; 21(7): 1214 - 1222. [Abstract] [Full Text] [PDF]

				M. E. Gleave, M. Elhilali, Y. Fradet, I. Davis, P. Venner, F. Saad, L. H. Klotz, M. J. Moore, V. Paton, A. Bajamonde, et al. Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma N. Engl. J. Med., April 30, 1998; 338(18): 1265 - 1271. [Abstract] [Full Text] [PDF]

				M. Sacchi, I. Klapan, J. T. Johnson, and T. L. Whiteside Antiproliferative Effects of Cytokines on Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, March 1, 1991; 117(3): 321 - 326. [Abstract] [PDF]